Aberrant promoter methylation profile in pleural fluid DNA and clinicopathological factors in patients with non-small cell lung cancer.
The aim of this study was to investigate the prognostic value of hypermethylation of tumor suppressor genes in patients with non-small cell lung cancer (NSCLC). In samples from 34 lung patients with malignant pleural effusions, we used a methylation-specific polymerase chain reaction to detect aberrant hypermethylation of the promoters of the DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT), p16INK4a, ras association domain family 1A (RASSF1A), apoptosis-related genes, death-associated protein kinase (DAPK), and retinoic acid receptor beta(RARbeta). There is no association between methylation status of five tumor suppressor genes including MGMT, p16INK4a, RASSF1A, DAPK and RARbeta in pleural fluid DNA and clinicopathological parameters including clinical outcome. Aberrant promoter methylation of tumor suppressor genes in pleural fluid DNA could not be a valuable prognostic marker of NSCLC patients with malignant pleural effusion.
Katayama
Hideki
H
Department of Medical Oncology, NHO Sanyo National Hospital, Yamaguchi, Japan.
Hiraki
Akio
A
Fujiwara
Keiichi
K
Matsuo
Keitaro
K
Maeda
Tadashi
T
Chikamori
Kenichi
K
Kishino
Daizo
D
Tajima
Kazuo
K
Ueoka
Hiroshi
H
Aoe
Keisuke
K
D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics* / Q000401:mortality; D019175:DNA Methylation; D004273:DNA, Neoplasm / Q000235:genetics*; D016147:Genes, Tumor Suppressor; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics* / Q000401:mortality; D016066:Pleural Effusion, Malignant / Q000235:genetics* / Q000401:mortality; D011379:Prognosis; D011401:Promoter Regions, Genetic; D016019:Survival Analysis
D004273:DNA, Neoplasm